Finally, although AGS-009, a humanised anti-INFα monoclonal antibody neutralising various IFN-α subtypes, showed good safety profile in a phase Ia RCT in adults with mild to moderate SLE,40,42 it was not further developed. This evidence concerns the gene IFNA17 and systemic lupus erythematosus.